Vestor Capital LLC Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Vestor Capital LLC bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELANGet Rating) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 79,372 shares of the company’s stock, valued at approximately $2,071,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CKW Financial Group boosted its holdings in shares of Elanco Animal Health by 36.4% in the 1st quarter. CKW Financial Group now owns 1,500 shares of the company’s stock valued at $39,000 after buying an additional 400 shares in the last quarter. MAI Capital Management boosted its holdings in shares of Elanco Animal Health by 7.1% in the 4th quarter. MAI Capital Management now owns 7,092 shares of the company’s stock valued at $201,000 after buying an additional 473 shares in the last quarter. FDx Advisors Inc. boosted its holdings in shares of Elanco Animal Health by 1.1% in the 1st quarter. FDx Advisors Inc. now owns 47,893 shares of the company’s stock valued at $1,250,000 after buying an additional 502 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Elanco Animal Health by 1.6% in the 1st quarter. Commonwealth Equity Services LLC now owns 36,654 shares of the company’s stock valued at $956,000 after buying an additional 591 shares in the last quarter. Finally, Resonant Capital Advisors LLC boosted its holdings in shares of Elanco Animal Health by 4.5% in the 1st quarter. Resonant Capital Advisors LLC now owns 14,294 shares of the company’s stock valued at $373,000 after buying an additional 614 shares in the last quarter.

Insider Transactions at Elanco Animal Health

In other news, Director R David Hoover acquired 10,000 shares of the company’s stock in a transaction dated Friday, May 20th. The shares were acquired at an average price of $23.33 per share, with a total value of $233,300.00. Following the purchase, the director now directly owns 125,000 shares of the company’s stock, valued at $2,916,250. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Stifel Nicolaus decreased their price objective on shares of Elanco Animal Health from $30.00 to $22.00 and set a “hold” rating for the company in a research report on Friday, June 24th. The Goldman Sachs Group lowered shares of Elanco Animal Health from a “buy” rating to a “sell” rating and decreased their price objective for the company from $32.00 to $19.00 in a research report on Thursday, July 21st. Morgan Stanley decreased their price objective on shares of Elanco Animal Health to $37.00 and set an “overweight” rating for the company in a research report on Tuesday, May 17th. Finally, Piper Sandler assumed coverage on shares of Elanco Animal Health in a research report on Monday, July 11th. They issued a “neutral” rating and a $22.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $26.40.

Elanco Animal Health Price Performance

ELAN traded up $0.42 during trading on Friday, reaching $19.44. 10,013,195 shares of the company’s stock were exchanged, compared to its average volume of 3,751,126. Elanco Animal Health Incorporated has a 1 year low of $18.64 and a 1 year high of $35.69. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.41 and a current ratio of 2.44. The company’s fifty day simple moving average is $20.98 and its 200-day simple moving average is $24.04.

Elanco Animal Health (NYSE:ELANGet Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.01. The business had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.22 billion. Elanco Animal Health had a negative net margin of 7.65% and a positive return on equity of 6.61%. The business’s revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the company earned $0.37 EPS. Analysts anticipate that Elanco Animal Health Incorporated will post 1.15 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

(Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANGet Rating).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.